Dr Matthew Coghlan Novo Nordisk
|
|
- Bruno Nathaniel Hawkins
- 5 years ago
- Views:
Transcription
1 Dr Matthew Coghlan Novo Nordisk
2 Preventing diabetes and its complications Matthew Coghlan PhD Senior Director Search & Evaluation Global Drug Discovery Novo Nordisk A/S
3 Obesity rates worldwide are increasing Men BMI 30 kg/m 2 Women BMI 30 kg/m 2 350M 350M 300M 250M 200M 150M 100M Number of people 300M 250M 200M 150M 100M Number of people 50M 50M M, million Sub-Saharan Africa Central Asia, Middle East and North Africa South Asia East and South East Asia High-income Asia Pacific Oceania Latin America and Caribbean High-income English speaking countries and Western Europe Central and Eastern Europe Adapted from NCD Risk Factor Collaboration (NCD-RisC). Lancet 2017:390;
4 Age-adjusted relative risk of developing T2D* Greater risk of developing T2D with higher BMI Relative risk of developing T2D with: BMI kg/m 2 = 28* BMI kg/m 2 = 40* BMI kg/m 2 = 54* BMI 35 kg/m 2 = 93* BMI (kg/m 2 ) *vs. BMI <22 kg/m 2 ; Data are for women only. n=114,281 female registered nurses aged years; T2D, type 2 diabetes Colditz et al. Ann Intern Med 1995;122:481 6
5 Weight change (kg) Cumulative incidence T2D (%) Weight loss reduces the risk of type 2 diabetes Adults with prediabetes Placebo Metformin Lifestyle changes % reduction Metformin = 18% reduction in risk Time (years) Time (years) n=2766 males and females. Knowler et al. Lancet 2009;374:
6 Lifestyle intervention
7
8 The Global Research Framework of Cities Changing Diabetes Prof. David Napier Global Academic Lead Cities Changing Diabetes
9 Today, two thirds of people with diabetes live in cities % OF PEOPLE WITH DIABETES LIVE IN URBAN AREAS % OF PEOPLE WITH DIABETES WILL LIVE IN URBAN AREAS 1 References 1. International Diabetes Federation. IDF Diabetes Atlas. 8th edn. Brussels, Belgium: International Diabetes Federation
10 Cities Changing Diabetes partnership working to bend the diabetes curve partner cities - Representing more than 120 million people Employers Mayor s office Planning and transport department Social service providers Patients groups Backbone Community groups Health department Researchers
11
12 Liraglutide is a once-daily, human GLP-1 analogue His Ala Glu Gly Thr Phe Thr Ser Asp Val Human endogenous GLP-1 Lys Glu Ala Ala Gln Gly Glu Leu Tyr Ser Ser Phe Ile Ala Trp Leu Val Lys Gly Arg Gly C-16 fatty acid (palmitoyl) T ½ = ~2 mins His Ala Glu Gly Thr Phe Thr Ser Glu Lys Glu Ala Ala Gln Phe Ile Ala Trp Leu Val Asp Val Ser Gly Glu Leu Tyr Ser Arg Gly Arg Gly Liraglutide 97% amino acid homology to human GLP-1; improved PK: albumin binding through acylation; heptamer formation Slow absorption from subcutis Resistant to DPP-4 Long plasma half-life (T ½ =13 h) DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; PK, pharmacokinetics; T ½, plasma half-life Knudsen et al. J Med Chem 2000;43:1664 9; Degn et al. Diabetes 2004;53:
13 Energy intake (kj) Liraglutide 3.0 mg reduces energy intake Individuals with obesity after 5 weeks of treatment Liraglutide 3.0 mg Placebo Appetite p= Satiety POMC/ CART Hunger NPY/ AgRP Arcuate nucleus Liraglutide Data are estimated means. In the post hoc analysis for total energy expenditure, body weight after 5 weeks of treatment was added to the original linear mixed-effect model Adapted from: van Can et al. Int J Obes 2014;38:784 93
14 Liraglutide 1.8 mg is not approved for weight management SCALE Phase 3a clinical trial programme SCALE Obesity and Prediabetes (1839) 1 SCALE Maintenance (1923) 3 Weight management and delayed onset of diabetes Liraglutide 3.0 mg n=2487 Placebo n=1244 Prevention of weight regain Liraglutide 3.0 mg n=212 Placebo n=210 SCALE Diabetes (1922) 2 SCALE Sleep Apnoea (3970) 4 Weight management in type 2 diabetes Liraglutide 3.0 mg n=423 Liraglutide 1.8 mg n=211 Placebo n=212 Effect of liraglutide in subjects with obesity and moderate to severe OSA Liraglutide 3.0 mg n=180 Placebo n=179 *SCALE, Sleep apnoea 3970 trial BMI 30 kg/m 2 plus co-morbidities; BMI, body mass index; OSA, obstructive sleep apnoea; SCALE, Satiety and Clinical Adiposity Liraglutide Evidence in individuals with and without diabetes 1. Pi-Sunyer et al. N Engl J Med 2015;373:11 22; 2. Davies et al. JAMA 2015;314:687 99; 3. Wadden et al. Int J Obes (Lond) 2013;37: ; 4. Blackman et al. Int J Obes (Lond). 2016;40:1310-9
15 Trial design: SCALE Obesity and Prediabetes Liraglutide 3.0 mg in weight management (160 weeks) Inclusion criteria: 18 years Stable BW BMI 30 kg/m 2 or 27 kg/m 2 + comorbidities Without prediabetes With prediabetes 1 Liraglutide 3.0 mg Placebo Liraglutide 3.0 mg (n=1505) Placebo (n=749) Trial information June 2011 to March 2015 Randomised controlled double-blind study 191 sites in 27 countries Lifestyle intervention: -500 kcal/day diet min/week physical activity Dose escalation 0 4 weeks Randomisation (2:1) Treatment duration 156 weeks 12-week off-drug FU 160 weeks End of trial Trial objective Efficacy of liraglutide 3.0 mg in delaying the onset of T2DM in participants with overweight/obese prediabetics Key endpoints Primary: time to onset of T2DM at 160 weeks Secondary: weight measures, glycaemic control variables, cardiometabolic risk factors, HRQoL, safety and tolerability 1. ADA. Diabetes Care 2010;33(Suppl. 1):S62 9 BW, body weight; D&E, diet and exercise; FU, follow-up; HRQoL, health-related quality of life; T2DM, type 2 diabetes mellitus le Roux et al. Lancet 2017;389:
16 Summary of baseline characteristics All randomised participants entering the 3-year treatment arms Liraglutide 3.0 mg (n=1505) Placebo (n=749) Sex, female 1141 (76) 573 (77) Sex, male 364 (24) 176 (23) Mean age, years 47.5 ± ± 11.8 White 1256 (83) 628 (84) Mean fasting body weight, kg ± ± 21.8 Mean BMI, kg/m ± ± 6.3 Mean HbA 1c, % 5.8 ± ± 0.3 Mean FPG, mmol/l 5.5 ± ± 0.5 Mean 2-hour PG during OGTT, mmol/l 7.4 ± ± 1.7 History of dyslipidaemia 499 (33) 249 (33) History of hypertension 635 (42) 312 (42) Data are observed means ± SD or number (%) FPG, fasting plasma glucose; OGTT, oral glucose-tolerance test; PG, plasma glucose; SD, standard deviation *The diagnoses of dyslipidaemia and hypertension were based on reported medical history le Roux et al. Lancet 2017;389:
17 Change in weight (%) Change in body weight (%) weeks 0-2 Liraglutide 3.0 mg Off-drug follow-up Observed mean LOCF Placebo Off-drug follow-up Observed mean LOCF ETD at week 160: 4.3% [ 4.9; 3.7] p< % -2.1% % -3.4% -6.1% -2.7% -5.2% % -8.5% -7.1% n= n= Week Full analysis set, fasting visit data only. Line graphs are observed means (±SE) LOCF, last observation carried forward; SE, standard error le Roux et al. Lancet 2017;389:
18 Participants (%) Participants diagnosed with T2DM over time Kaplan Meier plot: weeks Liraglutide 3.0 mg Off drug follow up Placebo Off drug follow up n= n= Week Full analysis set. Numbers in the figure correspond to the accumulated number of diagnosed participants T2DM, type 2 diabetes mellitus le Roux et al. Lancet 2017;389:
19 Liraglutide 3.0 mg label updates EU Summary of Product Characteristics SCALE Obesity and Prediabetes 160 week data 1 Published 22 Feb 2017 Liraglutide 3.0 mg (Saxenda ) EU Summary of Product Characteristics 2 Label updated approved 1 Dec 2016 In the 160 weeks part of trial 1 the weight loss occurred mainly in the first year, and was sustained throughout 160 weeks At week 160, while on treatment, 3% treated with Saxenda and 11% treated with placebo were diagnosed with type 2 diabetes mellitus The estimated time to onset of type 2 diabetes mellitus for patients treated with liraglutide 3.0 mg was 2.7 times longer (with a 95% confidence interval of [1.9, 3.9]), and the hazard ratio for risk of developing type 2 diabetes mellitus was 0.2 for liraglutide versus placebo 1. le Roux et al. Lancet 2017;389: : 2. Novo Nordisk. Saxenda Summary of Product Characteristics Available at: (accessed 10 May 2017);
20 NASH coincides with obesity, diabetes USA estimate NASH patient with co-morbidity NASH patient without co-morbidity % co-morbidity in NASH patients 20% 30% 10 million pts with NASH 65% 80% 70% 35% Majority of NASH patients have obesity and hypertension 25-50% of NASH patients have diabetes Obesity Hypertension T2DM Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 2011; 140: Armstrong MJ et al. Liraglutide safety and effi cacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: Neuschwander-Tetri BA et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: Ratziu V et al. Elafibranor, an Agonist of the Peroxisome Proliferator - Activated Receptor-a and -d, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 2016;150:
21 Obesity is an independent risk factor for NAFLD 2 1 Meta-analysis including 21 cohort studies including 13 prospective studies and 8 retrospective studies A total of 381,655 participants were included Obesity was associated with an approximately 3.5- fold increased risk of NAFLD after adjusting for Diabetes Dyslipidemia Blood pressure Physical activity Liver enzymes Alcohol intake Li et al., Obes Rev, 2016
22 Effect of weight loss on NASH/fibrosis Prospective study with bx-proven NASH Lifestyle changes over 52 weeks: kcal/d 2. Walk 200 mins/wk 3. Behavioural (/8wk) Overall (n=293) % weight loss achieved <5 n= n= n=25 10 n=29 Variables Overall (n=293) WL < 5 (n=205) WL = (n=34) WL = (n=25) WL 10 (n=29) Weight loss, % 3.8 ± ± ± ± ± 6.6 Resolution of steatohepatitis 72 (25) 21 (10) 9 (26) 16 (64) 26 (90) NASH, non-alcoholic steatohepatitis; WL, weight loss. Vilar-Gomez et al, Gastro, 2015.
23 Proportion of patients (%) Weight loss improves NASH liver fibrosis Prospective lifestyle modification* trial p= % 80% 60% Stabilized 40% 20% 0% n=73 n=16 n=8 n=16 Weight loss <5% Weight loss 5 7% Weight loss 7 10% Weight loss 10% Regressed Worsened Stabilized Regressed In patients with fibrosis at baseline, a 10% WL significantly reduced the fibrosis score by at least 1 point in 13 of 16 (81%). *Lifestyle changes are defined as consumption of 750 fewer calories daily, walking 200 minutes per week, and behavioural individual sessions every 8 weeks to promote adherence to diets. NASH, non-alcoholic steatohepatitis; WL, weight loss. Source: Vilar-Gomez E. et al. Gastroenterol. 2015;149:
24 COOH Semaglutide is a once-weekly GLP-1 analogue 94% homology to human GLP-1 t 1/2 of approximately 1 week His 8 Ala Aib Glu Amino acid substitution at position 8 (alanine to alpha-aminoisobutyric acid) protects against DPP-4 degradation Gly Thr Phe Thr Ser Asp Val Spacer and C-18 fatty diacid chain to lysine in position 26 provide strong binding to albumin spacer Amino acid substitution at position 34 (lysine to arginine) prevents C-18 fatty diacid binding at the wrong site Lys Ala Ala Gln Gly Glu Leu Tyr Glu 26 Phe 34 Ile Ala Trp Leu Val Lys Arg Gly Arg Ser Ser Gly DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; t 1/2, half-life Lau J et al. J Med Chem. 2015;58: ; Kapitza C et al. J Clin Pharmacol. 2015;55: ; Marbury TC et al. Diabetologia. 2014;57(Suppl. 1):S358.
25 Change in body weight (%) Semaglutide 0.4 mg OD showed improved weight reduction 11.5% reduction vs placebo Semaglutide Placebo -2.3 From a mean baseline weight of around 111 kg and a BMI of approximately 39 kg/m 2, a weight loss up to 17.8 kg was observed after 52 weeks of treatment with semaglutide This corresponded to a 13.8% weight loss compared to the weight loss of 2.3% achieved by diet, exercise and placebo alone, with all treatment arms adjusted for people discontinuing treatment in the study Semaglutide OD had a well-tolerated safety profile, with the most common adverse events being gastrointestinal side effects -16 N=957 people with obesity were treated with semaglutide or placebo for 52 weeks, followed by a 7 week follow-up. Mean baseline weight: 111 kg. Mean baseline BMI: 39 mg/m 2 BMI, body mass index; OD, once daily. O Neil et al. ENDO 2018; March 2018, Oral OR12-5.
26 26 Semaglutide for NASH PURPOSE AND MEDICAL RATIONALE NASH is associated with Obesity Diabetes Insulin resistance Inflammation Cardiovascular risk Potential benefits of GLP-1 receptor agonists Weight loss Improved glucose metabolism Improved lipid metabolism Reduced inflammation Resolution of NASH (LEAN study) 1 CVOT data in patients with T2D 2,3 Semaglutide has promising potential for NASH 1 Armstrong et al. Lancet 2016;387(10019), p Marso SP, et al. N Engl J Med 2016;375: Marso SP, et al. N Engl J Med. 2016; 375:311-22
27 Semaglutide NASH phase 2b dose-finding trial TRIAL NN patients Biopsy confirmed NASH Fibrosis stage 1-3 NAS 4 With or without T2D HbA1c 9.0% BMI kg/m 2 Liver biopsy (recent or new) Semaglutide 0.4 mg s.c. once daily Semaglutide 0.2 mg s.c. once daily Semaglutide 0.1 mg s.c. once daily Placebo 0.1 mg, 0.2 mg or 0.4 mg Duration 72 weeks 7 weeks follow up Liver biopsy Trial information Global trial FPFV: 30 Nov 2016 Randomised and double-blind Primary endpoint NASH resolution without worsening of fibrosis after 72 weeks Secondary endpoint At least one stage of liver fibrosis improvement with no worsening of NASH after 72 weeks
28 Semaglutide DEVELOPMENT STATUS Diabetes (s.c., QW) Obesity (s.c., QW) NASH (s.c., OD) Diabetes (oral, OD) OD, once daily; OW, once weekly; s.c., subcutaneous.
Novo Nordisk 10 Year Ambition for
Novo Nordisk 10 Year Ambition for Obesity disease: pathophysiology, Obesity consequences and management beyond weight loss significantly opened up the market by specifically addressing barriers across
More informationNon-alcoholic fatty liver disease: time to take note and manage. Philip Newsome Professor of Hepatology & Director of Centre for Liver Research
Non-alcoholic fatty liver disease: time to take note and manage Philip Newsome Professor of Hepatology & Director of Centre for Liver Research Disclosures Consultancy, Co-ordinating Investigator roles
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationWhere are we with Incretin Based Therapies for the Treatment of Diabetes?
Where are we with Incretin Based Therapies for the Treatment of Diabetes? Jens Juul Holst, NNF Center for Basic Metabolic Research Department of Biomedical Sciences Panum Institute, University of Copenhagen,
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationHow to apply novel outcome data. to clinical practice. Preventing Cardiovascular Disease in Patients with T2DM
Preventing Cardiovascular Disease in Patients with T2DM How to apply novel outcome data with GLP-1 RA to clinical practice Lars Rydén Department of Medicine K2 Karolinska Institutet Stockholm, Sweden Ljubljana
More informationWHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH?
WHAT CAN YOU USE IN YOUR CLINIC TODAY FOR THE TREATMENT OF NASH? Helena Cortez-Pinto Laboratório de Nutrição, FML, Serviço de Gastrenterologia, Hospital St Maria, Lisboa, Portugal EASL Governing Board:
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationTranslating GLP-1 trial outcomes to cardiology practice
Translating GLP-1 trial outcomes to cardiology practice Which patients will benefit? Lars Rydén Senior Professor Department of Medicine K2 Karolinska Institutet Stockholm, Sweden Munich August 27, 2018
More informationDiseases to Watch. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic
Diseases to Watch Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) - Prevalence and Symptoms - Risk Factors and Potential treatments - Target identification for NASH Robert
More informationUpdate on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI
Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none
More informationRole of incretins in the treatment of type 2 diabetes
Role of incretins in the treatment of type 2 diabetes Jens Juul Holst Department of Medical Physiology Panum Institute University of Copenhagen Denmark Diabetes & Obesity Spanish Society of Internal Medicine
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationA randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide
A randomised controlled clinical trial in type 2 diabetes comparing semaglutide to placebo and liraglutide This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly
More informationImplications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?
Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes? Boston, MA November 7, 213 Edward S. Horton, MD Professor of Medicine Harvard Medical School Senior Investigator
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationNonalcoholic Fatty Liver Disease in Children: Typical and Atypical
Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationApproaches to Addressing Incretin Deficiency. Non-Insulin Injectable Agents. Incretin Mimetics. Exendin-4 in the Gila Monster
Non-Insulin Injectable Agents Approaches to Addressing Incretin Deficiency Longer-acting analogs? (Incretin mimetics) GLP-1 Analogs Inhibition of inactivation? (Incretin enhancers) DPP-4 Inhibitors Drucker
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationAn Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications
REVIEW An Update on the Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications Naim Alkhouri, M.D.,*, and Andrea Scott, B.S.* Nonalcoholic fatty liver disease (NAFLD)
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationBARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS
BARIATRIC SURGERY AND TYPE 2 DIABETES MELLITUS George Vl Valsamakis European Scope Fellow Obesity Visiting iti Associate Prof Warwick Medical School Diabetes is an increasing healthcare epidemic throughout
More informationDulaglutide: designed with patients in mind
31 st Panhellenic Annual Congress of the Hellenic Association for the Study & Education of Diabetes Mellitus Thessaloniki 11 th, November 2017 Dulaglutide: designed with patients in mind Imre Pavo MD PhD
More informationFRANKFURT SITE TOUR 2017
FRANKFURT SITE TOUR 2017 MEDIA INFORMATION FRANKFURT SITE TOUR 2017 CONTENTS FRANKFURT INSULIN CITY... 4 5 DIABETES BACKGROUNDER... 6 DIABETES STATISTICS... 7 DIABETES MEDICINES... 8 IMAGE BANK... 9 NOTES...
More informationCase Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes Mellitus
Case Reports in Pediatrics Volume 2013, Article ID 703925, 4 pages http://dx.doi.org/10.1155/2013/703925 Case Report Off-Label Use of Liraglutide in the Management of a Pediatric Patient with Type 2 Diabetes
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationSTRATEGIES FOR SUSTAINING EXPOSURE OF PEPTIDE THERAPEUTICS: CASE STUDIES
STRATEGIES FR SUSTAINING EXPSURE F PEPTIDE THERAPEUTICS: CASE STUDIES ASIA TIDES KYT JAPAN 23 FEBRUARY 2017 CHRISTPHER A. RHDES, PH.D. PRESENTATIN UTLINE Delivery Technologies for Sustained Exposure of
More informationPage 1 of 14. Prepared July 2017
New Medicine Recommendation Liraglutide (Saxenda ) For use as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index
More informationType 2 diabetes and metabolic surgery:
Type 2 diabetes and metabolic surgery: Shouldn't we call it again again bariatric? Josep Vidal Obesity Unit. Endocrinology and Nutrition Department Hospital Clínic, University of Barcelona (Spain) What
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationMetabolically healthy obesity and NAFLD
News & Views Metabolically healthy obesity and NAFLD Giovanni Targher and Christopher D. Byrne Giovanni Targher is at the Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University
More informationAmino Acids. Amino Acids. Fundamentals. While their name implies that amino acids are compounds that contain an NH. 3 and CO NH 3
Fundamentals While their name implies that amino acids are compounds that contain an 2 group and a 2 group, these groups are actually present as 3 and 2 respectively. They are classified as α, β, γ, etc..
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationDr Karen McNeil Consultant Endocrinologist
Dr Karen McNeil Consultant Endocrinologist Aged 53 Type 2 Diabetes 2010 HbA1c 7.9% ACR 5.3 mg/mmol What treatment? MF 500 mg bd (misses midday dose) Control Symptoms, BGL Complications DR, DN, PN Associations
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationDIABETES. A growing problem
DIABETES A growing problem Countries still grappling with infectious diseases such as tuberculosis, HIV/AIDS and malaria now face a double burden of disease Major social and economic change has brought
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More informationDonna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico
Donna Tomky, MSN, C-ANP, CDE, FAADE Albuquerque, New Mexico Presented in Collaboration with New Mexico Health Care Takes On Diabetes Discuss the burden and challenges prediabetes presents in New Mexico.
More informationHow to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris
How to manage patients with NASH? Dr Raluca Pais Institute of Cardiometabolisme and Nutrition (ICAN) Hôpital Pitie Salpetrière, Paris CLINICAL CASE 1996. 54 years old female Department of Primary CV Prevention
More informationLiraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Clin Pharmacokinet (2016) 55:657 672 DOI 10.1007/s40262-015-0343-6 REVIEW ARTICLE Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics Lisbeth V. Jacobsen 1 Anne Flint
More informationFirst European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health
First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationSlide 1. Investor presentation. Meet the Management London, 9 August 2018
Slide 1 Investor presentation Meet the Management London, 9 August 2018 Manato diagnosed with type 1 diabetes Shirley Ohara, Adelia Stewart has type 2 diabetes Kanagawa, Japan New Orleans, Louisiana, US
More informationInvestigating general liver disease/transaminitis
BHIVA Autumn Conference London 14 October 2016 Investigating general liver disease/transaminitis Emmanuel A. Tsochatzis Senior Clinical Lecturer and Consultant Hepatologist Institute for Liver and Digestive
More informationThe Global Agenda for the Prevention of Diabetes: Research Opportunities
The Global Agenda for the Prevention of Diabetes: Research Opportunities William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology
More informationObjective: You will be able to explain how the subcomponents of
Objective: You will be able to explain how the subcomponents of nucleic acids determine the properties of that polymer. Do Now: Read the first two paragraphs from enduring understanding 4.A Essential knowledge:
More informationNAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain
NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal
More informationSlide 1. R&D strategy. Mads Krogsgaard Thomsen EVP and Chief Science Officer. ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A
Slide 1 R&D strategy Mads Krogsgaard Thomsen EVP and Chief Science Officer ZIHAO LI AND HIS MOTHER BING HAN, China Zihao has haemophilia A R&D strategy Slide 2 Forward-looking statements Novo Nordisk s
More informationSYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)
TITLE OF THE STUDY / REPORT No. / DATE OF REPORT INVESTIGATORS / CENTERS AND COUNTRIES Clinical Study Report Protocol BC20779: Multicenter, double-blind, randomized, placebo-controlled, dose ranging phase
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationPROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationSemaglutide the new kid on the block in the field of glucagonlike peptide-1 receptor agonists?
Editorial Page 1 of 5 Semaglutide the new kid on the block in the field of glucagonlike peptide-1 receptor agonists? Cristian Guja 1,2, Rucsandra Dănciulescu Miulescu 1,2 1 National Institute of Diabetes,
More informationObesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationAchieving Excellence in Diabetes. The Importance of Incremental Care
Achieving Excellence in Diabetes The Importance of Incremental Care Kieran Walshe MD MRCGP FRCPE GP and Diabetes Specialist Diabetes in Ireland 2015: Estimated prevalence of diabetes 5.5% Estimated prevalence
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationBiological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A
Biological systems interact, and these systems and their interactions possess complex properties. STOP at enduring understanding 4A Homework Watch the Bozeman video called, Biological Molecules Objective:
More informationUpdate on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic
Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics
More informationPRODUCT INFORMATION SAXENDA. liraglutide
PRODUCT INFORMATION SAXENDA liraglutide SAXENDA increases heart rate. The clinical significance of the increase in heart rate with SAXENDA is unclear. The effects of SAXENDA on cardiovascular morbidity
More informationGLOBAL VALUE DOSSIER FOR BARIATRIC SURGERY
GLOBAL VALUE DOSSIER FOR BARIATRIC SURGERY Prepared by: Barnaby Hunt Ossian Health Economics and Communications, Bäumleingasse 20, 4051 Basel, Switzerland Phone: +41 61 271 6214 E-mail: hunt@ossianconsulting.com
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More informationUpdate on Clinical Management
Non-Alcoholic Fatty Liver Disease Update on Clinical Management Lisa J. Yoo, D.O. Gastroenterologist Regional Gastroenterology INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is characterized by
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationPage 2: Baker IDI. Page 4: Baker IDI. Global & Regional Obesity. High income English speaking Light Blue. Global & Regional Severe obesity
Metabolic Update Patients selection and choice of procedure Professor John B Dixon MBBS, FRACGP, FRCP Edin, PhD NHMRC Senior Research Fellow Head of Clinical Obesity Research, Baker IDI Heart and Diabetes
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationEpidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk. Eberhard Standl
Epidemiology of Diabetes, Impaired Glucose Homeostasis and Cardiovascular Risk Eberhard Standl European Heart House Sophia Antipolis Thursday, June 17, 2010 IDF Diabetes Atlas 2009: Global Numbers Still
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationHealth outcomes & research objectives in (crosscultural)international
Health outcomes & research objectives in (crosscultural)international research Brian Oldenburg Professor of International Public Health & Associate Dean (Global Health and International Campuses) brian.oldenburg@monash.edu
More information1. Describe the relationship of dietary protein and the health of major body systems.
Food Explorations Lab I: The Building Blocks STUDENT LAB INVESTIGATIONS Name: Lab Overview In this investigation, you will be constructing animal and plant proteins using beads to represent the amino acids.
More informationOther Ways to Achieve Metabolic Control
Other Ways to Achieve Metabolic Control Nestor de la Cruz- Muñoz, MD, FACS Associate Professor of Clinical Surgery Chief, Division of Laparoendoscopic and Bariatric Surgery DeWitt Daughtry Family Department
More informationPre-diabetes. Dr Neel Basudev. GPSI Lambeth DICT, Diabetes Lead Lambeth CCG
Pre-diabetes Dr Neel Basudev GPSI Lambeth DICT, Diabetes Lead Lambeth CCG The Prevention of Diabetes Where has this come from? Pre-diabetes mellitus (PDM) Term introduced by Tommy G. Thompson (Health &
More informationCS612 - Algorithms in Bioinformatics
Spring 2016 Protein Structure February 7, 2016 Introduction to Protein Structure A protein is a linear chain of organic molecular building blocks called amino acids. Introduction to Protein Structure Amine
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationBiomarkers and undiagnosed disease
Biomarkers and undiagnosed disease Soham Al Snih, MD, Ph.D The University of Texas Medical Branch, Galveston, TX May 29, 2015 Mexico City, Mexico Biomarkers Broad subcategory of medical signs Objective
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationThe Global Research Framework of Cities Changing Diabetes. Prof. David Napier Global Academic Lead Cities Changing Diabetes
The Global Research Framework of Cities Changing Diabetes Prof. David Napier Global Academic Lead Cities Changing Diabetes Today, two thirds of people with diabetes live in cities 2017 65% OF PEOPLE WITH
More informationSlide 1. Winning with GLP-1. Lars Fruergaard Jørgensen President and CEO. ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes
Slide 1 Lars Fruergaard Jørgensen President and CEO ALEXANDRE DE GREGORIO, Brazil Alexandre has type 2 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the
More informationDiabetes and cardiovascular outcome trials. Cees J. Tack, internist
Diabetes and cardiovascular outcome trials Cees J. Tack, internist Take home messages (2013) Glucoseverlaging: beperkt effect op CV outcomes tijd nodig DPP-4 remmers: veilig, maar niet superieur Onverwachte
More informationPharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
More informationBiomolecules: amino acids
Biomolecules: amino acids Amino acids Amino acids are the building blocks of proteins They are also part of hormones, neurotransmitters and metabolic intermediates There are 20 different amino acids in
More informationFatty Liver Disease. Mark Thursz. Imperial College
Fatty Liver Disease Mark Thursz Imperial College Non-Alcoholic Fatty Liver Disease UK adult obesity (BMI>30) 1980: 6% [M], 8% [F]. 1997: 17% [M], 20% [F]. By 2004, 23.6% of men and 23.8% of women were
More informationChallenges of managing obese patients with type 2 diabetes
Challenges of managing obese patients with type 2 diabetes Barbara McGowan MBBS FRCP PhD Consultant Endocrinologist Honorary Senior Lecturer Guy s and St Thomas Hospital, London Outline of lecture Introduction
More informationLAB#23: Biochemical Evidence of Evolution Name: Period Date :
LAB#23: Biochemical Evidence of Name: Period Date : Laboratory Experience #23 Bridge Worth 80 Lab Minutes If two organisms have similar portions of DNA (genes), these organisms will probably make similar
More information(Who and) When should patients with obesity and impaired glucose regulation undergo metabolic surgery?
(Who and) When should patients with obesity and impaired glucose regulation undergo metabolic surgery? Alex Miras Senior Clinical Lecturer in Endocrinology Disclosures Fractyl Novo Nordisk Astra Zeneka
More information